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INCRETIN DYSREGULATION OF LYSYL OXIDASE:  
A NEW MECHANISM FOR DIABETIC BONE DISEASE 
NEHA SHRESTHA 
 
ABSTRACT 
 
The American Diabetes Association has determined that the number of people with 
diabetes in America was 30.3 million in 2015, and it is becoming increasingly more 
prevalent. Diabetes is a condition characterized by chronic hyperglycemia due to either 
insufficient insulin or reduced insulin sensitivity. Diabetes comes with a host of 
complications; one major complication is osteopenia, which increases fracture risks in both 
type 1 and type 2 diabetics14. The changes in diabetic bone may be due to reductions in 
lysyl oxidase (LOX) levels leading to decreased amounts of insoluble type 1 collagen 
fibers, which are necessary for bone strength28. LOX catalyzes oxidative deamination of 
the hydroxylysine and lysine side chains of the collagen molecules to create reactive 
aldehyde groups9,14,17. These aldehyde groups rapidly react with the lysine or 
hydroxylysine on the helical region of neighboring molecules of collagen fibrils, creating 
crosslinks between molecules leading to a mature cross-linked collagen matrix9,15,18. Our 
lab has now linked the LOX reductions in diabetes to incretins such as glucose-dependent 
insulinotropic peptide (GIP), which directly increases LOX, and anti-incretins such as 
dopamine, which reduces LOX by inhibiting GIP. Incretins and anti-incretins are gastric 
hormones released by the intestine in response to nutrient consumption4. Generally, 
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incretins are hormones that stimulate insulin secretion from the pancreas where as anti-
incretins inhibit that insulinotropic effect13,23. GIP is an incretin that also has an anabolic 
effect on bone in addition to its insulinotropic effect23. In diabetes there is an impaired 
cellular response to GIP in the pancreas, but its effects on the bone as related to diabetes 
are unknown. Additionally, it was observed in our lab that bone-derived LOX levels were 
decreased in diabetes while the serum level of anti-incretin gut-derived dopamine was 
vastly increased. Dopamine is known to inhibit GIP in the pancreas, but its effect on the 
bone was unknown.  
Prior to this experiment our lab had already started exploring a potential mechanism 
for diabetic osteopenia, where diabetes leads to an increase in gut-derived anti-incretin 
(dopamine), which interferes with GIP-stimulated LOX in osteoblasts. The decreased 
levels of LOX lead to lowered collagen integrity and a loss in trabecular bone structure. 
The current work is a sub-study within the larger aim to elucidate the mechanism for 
diabetic osteopenia. The aim of this study was to further verify the effects of dopamine by 
using amisulpride, a dopamine receptor antagonist, to determine if amisulpride could 
restore bone health in streptozotocin (STZ) induced diabetic mice. 
For this study C57BL/6 wild type mice were used. The mice were divided at 
random into three groups (N=10 per group) as follows: control (no STZ, no amisulpride), 
STZ diabetic (STZ, no amisulpride), and STZ + amisulpride. Twenty of the mice had low 
dose intraperitoneal injections of STZ for five days to induce diabetes and ten mice 
received vehicle injections for the control group. The mice were maintained diabetic or 
normal for 8 weeks, after which ten of the STZ mice received intraperitoneal injections of 
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amisulpride daily for a month. It was found that STZ induced diabetic mice had a 
significant decrease in LOX levels and insulin levels. Amisulpride was able to rescue the 
decreases in LOX levels but did not alter insulin levels. Furthermore, micro-CT analysis 
and picrosirius red histology of long bones indicated that there is a decrease in bone 
volume, impaired trabecular structure, and disorganized collagen matrix in the STZ 
diabetic group. These impairments could be rescued by amisulpride administration, giving 
further evidence to the new mechanism for diabetic osteopenia. The increase in anti-
incretin gut-derived dopamine signaling could be the cause of diabetic osteopenia. 
Inhibition of the anti-incretin gut-derived dopamine may possibly provide a therapeutic 
target for diabetic osteopenia.   
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INTRODUCTION 
 
Diabetes and Bone Fractures 
Diabetes is a condition characterized by chronic hyperglycemia due to either 
insufficient insulin, or reduced insulin sensitivity. The former is named type 1 diabetes 
(T1D) or insulin dependent diabetes mellitus, and the latter is type 2 diabetes (T2D) or non-
insulin dependent diabetes mellitus14. The American Diabetes Association has determined 
that the number of people with diabetes in America was 30.3 million in 2015, and it is 
becoming increasingly more prevalent. Diabetes comes with a host of complications; one 
major complication is weakened bones14. Both T1D and T2D can lead to the development 
of diabetic osteopenia, which is defined as a loss of bone mass due to a defect in bone 
formation caused by the deterioration of bone micro structures1. While T2D has been 
linked to increased bone mineral density there is still a 20% increased risk of hip fractures 
among type 2 diabetic men and women12. The higher bone mineral density could be due to 
the association of type 2 diabetes with increased weight. Even so diabetes (T1D and T2D) 
itself is a risk factor for fractures1, 12. Thus, it is important to note that the quantity of bone 
does not necessarily equate to the quality of bone. Lower quality of bone can lead to hip 
fractures, which can be very debilitating and lead to decreased mobility and an increase in 
sedentary time, further exacerbating other diabetic complications such as neuropathy and 
cardiovascular diseases1. Because of the anticipated rise in diabetes and associated 
complications, the study of diabetic bone disease is imperative.  
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In order to study diabetic bone disease in the research setting it is necessary to find 
a suitable animal model. There are many different models in existence, one of these is the 
streptozotocin (STZ) induced type 1 diabetic mouse model. STZ is a broad spectrum 
antibiotic that causes a cell-mediated immune reaction against pancreatic beta cells 
selectively11. Beta cell destruction leads to decreases in the body’s response to glucose 
since beta cells are the primary cells responsible for insulin secretion. STZ can be delivered 
as one-injection or as a multiple sub-dosage over a period of 5-6 days11. Approximately a 
week after STZ dosing there is an elevation in plasma glucose in mice due to a lack of 
insulin. This model of T1D has been verified. The STZ model of T1D closely resembles 
the spontaneously diabetic NOD mice mode14. Not only do these mice develop 
hyperglycemia, they also develop bone abnormalities14. These STZ mice have been shown 
to have trabecular bone loss and weakened bone structures14. In our lab we have selected 
the STZ treated C57BL/6 mice as a model to study the mechanisms of diabetic bone disease 
and their littermates as controls. They are an ideal model because we can study 
abnormalities related to diabetes, while holding other factors such as genetics constant 
between the diabetic and control littermate mice.  
 
Bone Composition  
Bones exist in a state of flux.  They are constantly remodeling in response to 
physiological and mechanical stimuli. Old or damaged bone is removed by osteoclasts and 
replaced with new bone by osteoblasts, in a very dynamic system6, 14. This continuous 
turnover is needed to maintain bone strength throughout our lives. Remodeling starts with 
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the removal of old bone in discrete packets, which are then replaced with new matrix 
protein that will become mineralized to form new bones6. Bone tissue is composed of 
mineral matrix (60 to 70%), organic matrix (20 to 40%), cells (osteoprogenitor, osteocyte, 
osteoblast, and osteoclast), water, and lipids14. The mineral portion of the bone is almost 
entirely hydroxyapatite, with some carbonate, magnesium, and acid phosphate3, 6. 
Hydroxyapatite are small inorganic molecules of calcium apatite (~200 angstroms) which 
are poorly soluble6. The mineral matrix of the bone provides the bone with its stiffness 
quality that determines its ability to resist deformation21. The organic matrix portion of the 
bone is primarily composed of type I collagen (about 90%)3, 21. The organic matrix provides 
the bone with tensile strength and ductility21. Both the mineral and the organic matrix 
components are necessary to resist stress and prevent bone fractures.  
In the past, focus has been on the mineral matrix phase such as bone mass, bone 
geometry, and mineral property. However, bone abnormalities are also seen in the organic 
matrix phase in many studies. In fact, it was determined that for the onset of diabetic 
osteopenia the organic matrix phase change is more critical and precedes the mineral phase 
changes27. In a recent study with Zucker Diabetic Fatty (ZDF) rats, no difference in the 
mineral density and mineral property was seen between diabetic ZDF (fa/fa) and non-
diabetic (-/fa) controls27. However, there were significant decreases in organic matrix in 
the diabetic bone, marked by decreases in insoluble collagen, potentially due to reduced 
lysyl oxidase (LOX) and lysyl oxidase like-1 (LOXL-1) expression in diabetes, which we 
will discuss later on27.  
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Collagen  
While both the mineral and the organic matrix are necessary components to resist 
stress and prevent fractures, the organic matrix changes seem to be more critical for the 
onset of diabetic osteopenia26, 27. Organic matrix is primarily composed of collagen 
(~90%), and collagen is the main structural protein in the extracellular matrix5, 18. There 
are at least 28 types of collagen that have been described according to their structure18. 
Most common type is named type 1 collagen, found in connective tissues and it is the 
principal component of extracellular bone matrix18, 19.  
In the bone, osteoblast cells make α chains of collagen consisting of a glycine-X-Y 
repeating amino acid motif which are composed of two α-1 chains (aka. COL1A1) and one 
α-2 chain (aka. COL2A1)21. When all three of the α-chains of collagen are made, a C-
terminal propeptide initiates the formation of a triple helical procollagen structure21. In 
addition to the helical structure, type 1 procollagen also has two non-helical domains called 
propeptides at the N- and C- terminal ends3, 21, 29. Once formed the modified type 1 
procollagens are secreted into the extracellular space where specific proteases cleave the 
Figure 1. Bone composition 
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ends releasing aminoterminal propeptide (PINP) and the carboxy-terminal propeptide 
(PICP), leaving behind on the collagen molecule shorter non-helical regions known as 
telopeptides. Released propeptides can be used to assess collagen biosynthesis18, 29. 
Modified type 1 procollagens, now termed tropocollagens, are then assembled in the 
extracellular matrix into type 1 collagen fibrils. Collagen fibrils aggregate extracellularly 
and undergo further modification, where covalent crosslinks are formed within and 
between molecules via a lysyl oxidase (LOX) catalyzed reaction finally resulting in a 
network of collagen molecules stabilized by covalent crosslinks resulting in mature 
collagen9, 18. The enzymatic cross-linking is critical for proper formation of the 
extracellular matrix, and thus for bone strength.  
 
 
 
 
 
 
 
Figure 2. Collagen biosynthesis adapted from: Mouw et al., (2014). 
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Lysyl Oxidase 
Collagen cross-links are formed via a lysyl oxidase catalyzed reaction. There are 
five members in the lysyl oxidase (LOX) family which include, lysyl oxidase (LOX) and 
lysyl oxidase like 1-4 (LOXL1-4)24. The most prominent forms of LOX present in the bone 
are LOX and LOXL1, while LOXL2, LOXL3, and LOXL4 are not expressed very much19. 
All of the LOX family members have a conserved C-terminal region and a variable N-
terminal region24. In general, LOX is a copper containing metalloenzyme that requires 
lysyl-tyrosyl quinone (LTQ) as a cofactors18, 22. LOX is well known to be a required 
enzyme for proper elastin and collagen cross-linking18. The enzyme works via a ping-pong 
mechanism, where lysine and hydroxylysine side chains of the collagen molecule goes 
though oxidative deamination by LOX to create allysines (reactive aldehyde group) while 
LOX itself is reduced9, 17. The reduced enzyme is then re-oxidized and regenerated 
releasing hydrogen peroxide9. The allysines that are created by oxidative deamination will 
rapidly react with the lysine or hydroxylysine on the helical region of neighboring 
molecules of collagen fibrils and with residues within the non-helical telopeptides of a 
triple helix, creating crosslinks between and within molecules which will react further to 
result in a variety of stabilizing structures15, 18.  
 
Collagen Crosslinking and Bone Properties 
Collagen networks play a key role in bone toughness. In a study by Wang et.al, it 
was found that the integrity of the bone decreases as the degree of collagen denaturation 
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increases26. In their experiment collagen denaturation was achieved by heating normal, 
non-diabetic bone. They found that the increases in collagen denaturation had a differential 
effect on the toughness versus the stiffness of the bone; the toughness of the bone was 
affected, but the stiffness of the bone was not altered26. Additionally, in STZ induced T1D 
and in T2D models, collagen cross-linking impairments are seen to occur with no changes 
in the bone mineral density but with increased bone fragility22. Because LOX is necessary 
for collagen cross-linking, it can be said that impaired enzymatic cross-linking by LOX 
impacts bone fragility.  
The importance of LOX cross-linking has also been demonstrated by the inhibition 
of LOX by β-aminopropionitrile (BAPN). BAPN is a LOX inhibitor that, in a dose- 
dependent fashion, inhibits cross-link formation and maturity, directly reducing bone 
strength15. Additionally, LOX -/- mice have been created. While this genotype is not viable, 
as the fetus is able to come to term but dies shortly after, in comparison to age-matched 
WT fetuses the LOX -/- have decreased collagen fibril diameter and altered early and late 
stage of osteoblast differentiation19. The role of LOX was also directly examined by Xiao 
et al., where they showed that in Zucker diabetic fatty (homozygous leptin receptor mutant) 
(ZDF) there is a decrease in the tensile strength in the rat femur which was accompanied 
with a decrease in mature collagen, LOX, and LOXL1, as compared to lean Zucker rats 
(heterozygous leptin receptor mutant)27. In these rats there was no change in the mineral 
portions of the femur, only the dysregulation in collagen cross-linking due to LOX. Taken 
together, we can conclude that the structural component of the bone that is critical for bone 
related changes in diabetes is the organic matrix. Organic matrix is composed mainly of 
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type 1 collagen which requires LOX for cross-linking. In diabetic bone, there is a decrease 
in the expression of LOX and LOXL1 that can lead to the decrease in collagen cross-
linking, causing osteopenia.  
Prior to the current study, our lab had already determined that STZ induced diabetic 
mice have a decrease in LOX expression (Figure 3), specifically LOX and LOXL1 (Figure 
4) in primary osteoblasts. However, it was still unknown what caused the LOX and LOXL1 
expression to decrease in diabetic bones. Additionally, it was seen that the decrease in LOX 
was accompanied by vast increase in an anti-incretin, a gastric hormone, gut-derived 
dopamine (Figure 5). Because there could be a potential link between incretins, anti-
incretins, and LOX, we explored the potential roles of these gut derived hormones.  
 
 
Figure 3. LOX protein is decreased in diabetes in primary bone cell cultures.  
Primary bone cells were plated at a density of 5 x 103 cells per cm2 in 10 cm plate, 
lysed after 4 days, and assessed for LOX protein by western blot. N=4 per group, 
each lane represents a separate mouse. Credit: Eileen Daily 
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Incretins and Anti-Incretins  
Incretins are hormones that are secreted from the intestine due to nutrient 
consumption7, 23. There are two main incretin hormones: glucose dependent insulinotropic 
peptide (GIP), which are produced by the K cells in the upper small intestine, and glucagon-
like peptide-1 (GLP-1), which are produced by the L cells in the lower intestine and 
colon7,23. Both are known to be insulinotropic in the pancreatic beta-cells, but they have 
many distinct roles outside of the pancreas23. In the bone, GIP promotes bone formation by 
directly interacting with osteoblasts while, GLP-1 inhibits bone absorption but does not 
Figure 4. LOX and LOXL1 RNA levels are decreased in diabetes in primary bone 
cell cultures. A) Absolute quantification of LOX isoforms in control bone cells. B) 
Relative quantity of LOX isoforms in diabetic primary bone cells as compared to 
% of control. Data are means +/- SE, *p<0.05, **p<0.01, ***p<0.001 by student’s 
T-test (N=5 per group). Credit: Eileen Daily 
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directly interact with osteoblasts or osteoclasts23. The focus of our study has been on GIP 
and its anabolic effects on the bone.  
GIP is a 42-amino acid peptide which is derived from a 153-amino acid precursor 
encoded by the GIP gene23. GIP levels are low during fasting and rapidly rises after nutrient 
consumption7,23. It is degraded quickly by dipeptidyl peptidase 4 (DPP4) by conversion to 
an inactive GIP within minutes7. In the pancreatic beta cells GIP exerts its effect by binding 
specifically to glucose-dependent insulinotropic polypeptide receptor (GIPR), which 
activates adenylyl cyclase to increase intercellular cAMP levels and Ca2+7, 23. In addition 
to the pancreas, GIPR is also expressed on the surface of various different tissues such as 
the brain, heart, and bone7,23. In the bone GIPR is expressed on the surface of osteoblast 
bone cells. In MC3T3 osteoblasts, a bone cell line, GIP has been shown to dose-
dependently increase LOX and collagen maturity through the adenylyl cyclase-cAMP 
pathway, similar to that seen in the pancreatic beta cells16.  
The importance of GIPR in bone can be seen in various mouse studies. GIPR -/- 
mice have decreased bone strength and material properties similar to that seen in diabetic 
osteopenia while GIPR overexpression results in increased bone mass25, 28. Additionally, 
mutated GIPR results in a reduction in bone mass and altered turnover where bone 
formation in decreased but has no effect on reabsorption7, 8. In diabetes there is actually an 
increase in the concentration of GIP, however, it is not able to elicit a response23. The 
inability of GIP to elicit a response could partly be due to the effects of anti-incretins which 
suppress the effects of incretins. Normally, anti-incretins and incretins play a role in 
maintaining homeostasis13. One such anti-incretin is gut-derived dopamine; it was 
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determined in our lab that in STZ induced T1D mice, the serum dopamine levels are 
increased (Figure 5). The increased levels of gut-derived dopamine could potentially lead 
to the attenuation of the GIP effect, as dopamine will have an anti-incretin effect. To study 
the role of gut-derived dopamine we employed amisulpride, a dopamine receptor 
antagonist20.  Amisulpride is a second generation benzamide structural class antipsychotic, 
it is currently approved in Europe for the treatment of schizophrenia20. It had already been 
observed that, with amisulpride administration, there was increased insulin secretion, but 
the cause was unknown20. We saw that bone impairments could be rescued by amisulpride 
administration, giving further evidence to the new mechanism for diabetic osteopenia. 
Anti-incretin gut-derived dopamine could be key to diabetic osteopenia, potentially by 
interfering with the effects of GIP, and decreasing LOX, thus, directly decreasing collagen-
crosslinking.  
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Figure 5. Diabetic Mice have increased serum dopamine levels. Data are means 
+/- SD, *p<0.05 by student’s T-test, N=10 per group. 
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METHODS  
  
 
Mouse Model and Tissue Collection 
 
To study diabetic osteopenia, 8 week old male and female wild type C57BL/6 
(Jackson Laboratory) mice were used. The Boston University Institutional Animal Care 
and Use Committee (IACUC) approved all animal protocols used. The animals were 
housed in standard condition with 12 hours light/dark cycle and ad libitum food and water. 
A total of twenty wild type mice were made diabetic by low dose streptozotocin (STZ) 
(Sigma Aldrich catalogue #S0230) intraperitoneal (IP) injections. The mice were IP 
injected for five consecutive days at a dose of 40 mg/kg. STZ was dissolved in 0.1 M 
sodium citrate buffer, pH 4.5. The control mice were injected with vehicle consisting of 
0.1 M sodium citrate buffer pH 4.5. All of the STZ injected mice became diabetic within a 
week of the final injection, while the vehicle injected mice remained non-diabetic. Diabetic 
status was confirmed by two consecutive blood glucose readings that were >250 mg/dL. 
Mice were maintained diabetic or normal and their blood glucose was monitored twice a 
week for 8 weeks, allowing bone phenotype to occur. Blood glucose was monitored by tail 
vein puncture, a drop of blood was acquired and placed directly on OneTouch Ultramini 
blood glucose meter and corresponding blood glucose test strips. None of the mice were 
given insulin during the course of this experiment.  
Following the 8 weeks of diabetic status, the STZ treated mice were divided into 
two groups, amisulpride or vehicle. The groups were IP injected daily for 4 weeks with 
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either Ultra-pure amisulpride (Sigma Aldrich, catalog #A2729) at a concentration of 10 
mg/kg or vehicle. Amisulpride is a dopamine receptor antagonist and an atypical 
antipsychotic. Ultra-pure amisulpride was dissolved in cell culture grade DMSO, and 
further dissolved in PBS for a final concentration of 2% DMSO. The vehicle consisted of 
2% DMSO in PBS.  
At the end of the injection series mice were sacrificed by isoflurane inhalation 
followed by cervical dislocation. Blood was collected from the heart for use in a separate 
study, data not shown. The mice were than rinsed in 70% ethanol and an incision was made 
around the perimeter of the hind limbs where they attach to the trunk. The skin was 
removed from the area to minimize contamination and the hind limbs were removed from 
the body. The hind limbs were bisected into femur and tibiae by cutting through the knee 
joint. Femurs from three of the control mice and both tibiae of the STZ treated mice and 
the STZ + amisulpride treated mice were scraped clean of muscles and connective tissues 
and used for primary cell culture. The left femur and spines were dissected and cleaned. 
They were wrapped in gauze and placed in PBS for micro-computed tomography (micro-
CT) analysis. The right femur was fixed in 4% paraformaldehyde and decalcified in 20% 
EDTA for 2 weeks and used for histology. These femurs were paraffin embedded with the 
intercondylar notch at the distal end facing upward and sectioned by Center for Skeletal 
Research (P30 AR066261) histology core at Massachusetts General Hospital.  
 
 
 
 15 
Cell Culture and Analysis of LOX RNA 
 
Primary osteoblasts were isolated from the femurs of 3 control mice and both tibiae 
of the treated mice. The femurs and tibiae were cut into 1-2 mm2 pieces using sterile 
scissors. The fragments were placed in 5 mL culture flask and washed in PBS, 4 mL 
collagenase II solution was then added to the flask and incubated at 37oC on a shaker for 2 
hours. Collagenase II solution was made fresh at the time of use by adding 2 mg of 
collagenase II powder (Thermofisher Scientific catalog  #17101015) per 1 mL DMEM. 
The bone fragments were then rinsed three times in DMEM supplemented with 100 µg/mL 
ascorbate and 10% FBS. The bone fragments were transferred to a 25 cm2 flasks with 5 mL 
medium, there were around 20 fragments per flask. After 4 days, cells began to migrate out 
of the bone, at this point both the cells and medium were harvested for RNA isolation. 
RNA was extracted by direct lysis of the cells for RT-qPCR using Taqman probes for LOX 
(Mm00495386_m1). Data was calculated using the 2-(ΔΔCT) method as described 
elsewhere, data is represented as a relative fold change as compared to control non diabetic 
mice.  
 
Micro-Computed Tomography (μ-CT) 
 
 The left femurs and L5 vertebrae of the mice were used for micro-computed 
tomography (micro-CT). All imaging and analysis was performed at micro-CT Imaging 
Core Facility at Boston University using a Scanco Medical µCT40 Scanning instrument 
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(Brütisellen, Switzerland). The following setting were held constant for all samples, power 
at 70 kVp, current at 113 μA, integration time of 200 msec, all samples were scanned at a 
resolution of 12 microns/voxel. Trabecular compartments of the distal metaphysis of the 
femur was selected for trabecular analysis, vertebral analysis is yet to be done. Trabecular 
region of interest was defined as, 60 microns removed from the end of the growth plate and 
which extended 1200 microns proximal of the growth plate. 2-D tomograms were manually 
traced to designate trabecular regions.  
 
Picrosirius Red Staining 
 
 
 Picrosirius red stain was used to analyze collagen organization. The stain was made 
by adding 0.5 g of Sirius Red dye (Direct Red 80, Sigma Aldrich catalogue #43665) to 500 
mL saturated aqueous picric acid. Sections were stained for an hour in the mixture and 
counterstained with Weigert’s hematoxylin. An Olympus IX70 microscope with and 
without polarizing filters (Olympus Inc., Tokyo, Japan) was used to image the sections. 
The region of interest was defined as 2 mm down and 2 mm to the right from the center of 
the growth plate. The blue, green, yellow, orange, and red content of each image was 
qualitatively analyzed. The blue, green, darker shades indicate a healthier state with better 
collagen organization, whereas the yellow, orange, brighter shades indicate a more 
disorganized state of collagen.  
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RESULTS 
  
 
 Eight-week old C57BL/6 mice that were injected with STZ developed diabetes 
within a week of the last STZ injection while the vehicle-injected mice remained normal 
(Figure 6). Diabetes was defined as a blood glucose reading above 250 mg/dL for at least 
two consecutive readings. Mice were maintained diabetic for 8 weeks and were further 
divided into amisulpride or vehicle groups. The STZ + amisulpride mice started to have a 
decrease in their blood glucose following the amisulpride injections but remained above 
250 mg/dL, while the STZ only group continued an upward trend in their blood glucose 
levels. 
 
 
Figure 6. Descriptive Analysis of Blood Glucose Reading 
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Amisulpride treatment rescues LOX expression in STZ induced diabetic mice. 
 
RNA isolated from primary bone cells of control, STZ diabetic, and STZ + 
amisulpride mice were used to determine LOX RNA expression (Figure 7). The STZ 
treated diabetic mice had a significantly decreased LOX expression as expected of T1D 
mice. The decrease in LOX due to the diabetic condition was rescued greatly by in vivo 
amisulpride administration. Amisulpride is able to rescue the decreased expression of LOX 
in diabetic mice.  
 
 
Figure 7. LOX expression is reduced in diabetic bone and rescued by amisulpride 
treatment in vivo. Data represent fold change calculated using the 2-(ΔΔCT) method 
relative to the control non diabetic mice; *p<0.05, **p<0.01, ***p<0.001 by 
students T-test. N=10 per group. 
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IP injections of amisulpride restores normal bone phenotype in diabetic mice. 
 
 The left femurs of mice were used for micro-CT. It was observed that in vivo IP 
injection of amisulpride, a dopamine receptor antagonist, restores bone phenotype as 
analyzed by micro-CT 3D tomography (Figure 8). The bone volume over total volume is 
greatly reduced while the trabecular spacing is increased in the STZ diabetic mice. 
Treatment with amisulpride after 8 weeks of maintained diabetic status greatly improves 
the observed phenotype, there was an increase in the bone volume over total volume and a 
decrease in the trabecular spacing.  
 Additionally, the collagen profile is greatly improved by amisulpride. Picrosirius 
red stain was used to analyze collagen organization. Picrosirius red stains all collagenous 
connective tissue. When viewed by polarized microscopy thinner more organized areas 
appear more green and darker, while thicker disorganized areas appear more red and 
brighter. The diabetic mice have an increased amount of yellow and red and appear 
brighter. The amisulpride treated mice have a femur profile that more closely match the 
control mice.  
 
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. In vivo IP administration of amisulpride can restore diabetic bone in 
mice. A) Micro-CT 3D tomography reconstruction of femoral distal metaphysis in 
control, STZ diabetic, and STZ + amisulpride mice. B) Trabecular parameters, 
bone volume/total volume (BV/TV) and Trabecular spacing (Tb.Sp). Student’s T-
test, N=3 
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Figure 9. Collagen profile of the amisulpride treated mice more closely resemble 
the control mice as compared to the STZ diabetic mice. Picrosirius red staining of 
collagen under polarized light. A) Non-Diabetic Control B) STZ-Diabetic C) STZ 
+ Amisulpride. 
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DISCUSSION 
 
 
Diabetes continues to grow more prevalent in the world. As the diabetic 
population grows its associated risk of osteopenia and hip fracture will need to be 
addressed. The current work was a sub-study of a much larger undertaking by our 
lab to understand the mechanisms of diabetic osteopenia. Our lab had already 
established many new novel associations to diabetic osteopenia by linking incretin 
and anti-incretins to LOX levels in the bone. We know that there is a decrease in LOX 
levels in diabetes and the aim of our lab was to determine why. The interesting bit of 
data that led to the current study was the finding that, as LOX levels decrease in 
diabetes, the anti-incretin gut-derived dopamine levels increase. Since we know that 
GIP can stimulate LOX, and anti-incretins such as gut-derived dopamine can inhibit 
GIP, it was possible that gut-derived dopamine was directly linked to lowering LOX 
levels in diabetic bone. Much of the work was done in cell culture and we hoped to 
verify the effects of dopamine by using amisulpride, a dopamine receptor antagonist, 
in vivo. The hypothesis was that if we inhibit the dopamine attenuation of GIP, we 
could reverse some of the damage to the bone caused by diabetes.  
Using LOX levels as a marker for bone health, we can see clearly in Figure 7, 
that amisulpride could reverse the damage to the bone by increasing LOX levels. It 
can be assumed that as LOX levels increase, so does bone health. The micro-CT data 
corroborate that, with amisulpride treatment, there was a significant increase in the 
trabecular bone structure. It was interesting to see that there was such a remarkable 
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difference in the diabetic mice and the amisulpride treated mice. Additionally, the 
picrosirius red histology of long bones gave evidence of improved collagen 
organization.  
In this study we used STZ to induce T1D in C57BL/6 wild-type mice. 
Streptozotocin was an ideal way to study diabetic bone for us, because it allowed for 
greater control. We were able to use littermates as controls, keeping genetic 
variations lower. All of the STZ injected mice became diabetic, it was interesting to 
see that with the amisulpride treatment the blood glucose levels began to drop, 
though they remained diabetic throughout the course of the study. It is possible that 
in an extended study the blood glucose levels would eventually become <250 mg/dL, 
our cut off for diabetes. It had previously been seen that amisulpride has an anti-
diabetic effect on oral glucose tolerance test (OGTT) in DIO diabetic mice20.  
Amisulpride is an atypical antipsychotic that is already on the market 20. It is a 
drug typically used for schizophrenia, but in clinical settings it has been observed to 
cause insulin secretion20.  It is possible that both the insulin effect and the LOX effect 
is due to amisulprides role as an anti-anti-incretin. For example, amisulpride is 
perhaps able to inhibit the effects of dopamine in both the pancreas and the bone. 
This would allow incretins such as GIP to have both a greater effect as an 
insulinotropic factor in the pancreas and an anabolic effect in bone.  
We did not determine the behavioral effects of amisulpride. Since it is an 
antipsychotic, it is possible that it can have major behavior effects. This would need 
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to be further investigated. Additionally, we used a T1D model; we can assume that 
there would be similar results with a T2D model, but it would need to be verified. 
In the context of the lager study the current experiment with amisulpride 
administration in T1D mice gives further evidence for the new mechanism for 
diabetic osteopenia. The increase in the anti-incretin gut-derived dopamine may be 
the causal path to diabetic osteopenia; and the inhibition of gut-derived dopamine 
with a dopamine antagonist, such as amisulpride, could provide a potential new 
therapeutic strategy.  
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